Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer

F. Schettini, M. Giuliano, M. Lambertini, R. Bartsch, D.J. Pinato, C.E. Onesti, N. Harbeck, D. Luftner, S. Rottey, P.A. van Dam, K. Zaman, G. Mustacchi, J. Gligorov, A. Awada, M. Campone, H. Wildiers, A. Gennari, V.C.G. Tjan-Heijnen, J. Cortes, M. LocciI. Paris, L. Del Mastro, S. De Placido, M. Martin, G. Jerusalem, S. Venturini, G. Curigliano, D. Generali*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Citation (Web of Science)

Abstract

Simple Summary Anthracyclines are among the most active chemotherapies in breast cancer (BC). However, they can cause structural and cumulative dose-related cardiac damage; hence, they require careful administration after preliminary functional cardiac assessment and subsequent monitoring, along with a limitation in the cumulative dose delivered. Non-pegylated liposomal doxorubicin (NPLD) has been precisely developed to optimize the doxorubicin toxicity profile, while retaining its therapeutic efficacy, thanks to a reduced diffusion in normal tissues with preserved drug penetrance into cancer sites. This has allowed administration of NPLD beyond a conventional doxorubicin maximum cumulative dose, as well as in patients with cardiac comorbilities or anthracycline pretreatment. At present, NPLD is approved in Europe and Canada in combination with cyclophosphamide as the first line of metastatic HER2-negative BC. However, given the increasing complexity of the therapeutic scenario in this setting, we have carefully revised the most updated literature on the topic and dissected the potential role of NPLD in the evolving therapeutic algorithms. Anthracyclines are among the most active chemotherapies (CT) in breast cancer (BC). However, cardiotoxicity is a risk and peculiar side effect that has been limiting their use in clinical practice, especially after the introduction of taxanes. Non-pegylated liposomal doxorubicin (NPLD) has been developed to optimize the toxicity profile induced by anthracyclines, while maintaining its unquestionable therapeutic index, thanks to its delivering characteristics that increase its diffusion in tumor tissues and reduce it in normal tissues. This feature allows NPLD to be safely administered beyond the standard doxorubicin maximum cumulative dose of 450-480 mg/m(2). Following three pivotal first-line phase III trials in HER2-negative metastatic BC (MBC), this drug was finally approved in combination with cyclophosphamide in this specific setting. Given the increasing complexity of the therapeutic scenario of HER2-negative MBC, we have carefully revised the most updated literature on the topic and dissected the potential role of NPLD in the evolving therapeutic algorithms.
Original languageEnglish
Article number4421
Number of pages17
JournalCancers
Volume13
Issue number17
DOIs
Publication statusPublished - 1 Sep 2021

Keywords

  • anthracyclines
  • breast cancer
  • triple negative
  • hormone receptor
  • metastatic
  • non-pegylated liposomal doxorubicin
  • PHASE-III TRIAL
  • TRASTUZUMAB PLUS DOCETAXEL
  • ENCAPSULATED DOXORUBICIN
  • 1ST-LINE THERAPY
  • NAB-PACLITAXEL
  • CONVENTIONAL DOXORUBICIN
  • PRIMARY CHEMOTHERAPY
  • MULTICENTER TRIAL
  • CYCLOPHOSPHAMIDE
  • EPIRUBICIN

Cite this